Renal disease: Environment, race, or genes?

Ethnicity and Disease

Volumn 16, Issue SUPPL. 2, 2006, Pages

  Adler, Sharon ^a,b  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetic nephropathy; Nephropathy risk

Indexed keywords

DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETIC RISK; GLOMERULUS FILTRATION RATE; HEREDITY; HUMAN; KIDNEY DISEASE; LINKAGE ANALYSIS; MEDICAL RESEARCH; RACE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; AFRICAN AMERICAN; AMERICAN INDIAN; ASIAN AMERICAN; ETHNOLOGY; GENETIC POLYMORPHISM; GENETICS; RISK FACTOR; UNITED STATES;

AFRICAN AMERICANS; AMERICAN NATIVE CONTINENTAL ANCESTRY GROUP; ASIAN AMERICANS; DIABETIC NEPHROPATHIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; RISK FACTORS; UNITED STATES;

EID: 33746090961     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Steinbrook R. Disparities in health care - From politics to policy. N Engl J Med. 2004;350:1486-1488.
2. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42(6 Suppl 5):A5-A7.
3. Bonds DE, Zaccaro DJ, Karter AJ, et al. Ethnic and racial differences in diabetes care: the insulin resistance atherosclerosis study. Diabetes Care. 2003;26:1040-1046.
4. Gary TL, McGuire M, McCauley J, et al. Racial comparisons of health care and glycemic control for African American and White diabetic adults in an urban managed care organization. Dis Manag. 2004;7:25-34.
5. Krop JS, Coresh J, Chambless LE, et al. A community-based study of explanatory factors for the excess risk for early renal function decline in Blacks vs Whites with diabetes: the atherosclerosis risk in communities study. Arch Intern Med. 1999;159:1777-1783.
6. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with White patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
7. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793-808.
8. Lasker RD. The Diabetes Control and Complications Trial. Implications for policy and practice. N Engl J Med. 1993;329:1035-1036.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
10. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419.
11. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
12. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
13. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
14. Lewis EJ, Hunsicker L, Bain RP, et al. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropamy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462. Erratum in: N Engl J Med. 1993;330:152.
15. Perneger TV, Whelton PK, Klag MJ, et al. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994;331:1675-1679.
16. Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Neprhol. 2003;14:2934-2941.
17. Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2003;42:22-35.
18. Adler S. Diabetic nephropathy: linking histology, cell biology, and genetics. Kidney Int. 2004;66:2095-2106.
19. Helig CW, Concepcion LA, Riser BL, et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest. 1995;96:1802-1814.
20. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes. 1997;46:1829-1839.
21. Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320:1161-1165.
22. Freedman BI, Spray BJ, Tuttle AB, et al. The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis. 1993;21:387.
23. Freedman BI, Tuttle AB, Spray BJ, et al. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1995:25:710-713.
24. Borch-Johnsen K, Norgaard K, Hommel E, et al. Is diabetic nephropathy an inherited complication? Kidney Int. 1992;41:719-722.
25. McCance DR, Hanson RL, Pettitt DJ, et al. Diabetic nephropathy: a risk factor for diabetes mellitus in offspring. Diabetologia. 1995;38:221-226.
26. Pettitt DJ, Saad MF, Bennett PH, et al. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:438-443.
27. Quinn M, Angelico MC, Warram JH, et al. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia. 1996;39:940-945.
28. Provoost AP, Shiozawa M, Van Dokkum RP, et al. Transfer of the Rf-1 region from FHH onto the ACI background increases susceptibility to renal impairment. Physiol Genomics. 2002;2:123-129.
29. Freedman BI, Rich SS, Yu H, et al. Linkage heterogeneity of end-stage renal disease on human chromosome 10. Kidney Int. 2002;62:770-774.
30. Iyengar SK, Fox KA, Schachere M, et al. Linkage analysis of candidate loci for end-stage renal disease due to diabetic nephropathy. J Am Soc Neprhol. 2003;14:S195.
31. Coresh J, Jaar B. Further trends in the etiology of end-stage renal disease in African-Americans. Curr Opin Nephrol Hypertens. 1997;6:243-249.
32. Cowie CC, Port FK, Wolfe RA, et al. Disparities in incidence of diabetic end-stage renal disease according to face and type of diabetes. N Engl J Med. 1989;321:1074-1079.
33. McGill MJ, Donnelly R, Molyneaux L, et al. Ethnic differences in the prevalence of hypertension and proteinuria in NIDDM. Diabetes Res Clin Pract. 1996;33:173-179.
34. Freedman BI, Bowden DW. The role of genetic factors in the development of end-stage renal disease. Curr Opin Nephrol Hypertens. 1995;4:230-234.
35. Nelson RG, Knowler WC, McCance DR, et al. Determinants of end-stage renal disease in Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus and proteinuria. Diabetologia. 1993;36:1087-1093.
36. Fioretto P, Steffes MW, Barbosa J, et al. Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes. 1999;48:865-869.
37. Fox CS, Yang Q, Cupples LA, et al. Genome-wide linkage analysis to serum creatinine, GFR, and creatinine clearance in a community-based population: the Framingham Heart Study. J Am Soc Nephrol. 2004;15:2457-2461.
38. Ng DP, Krolewski AS. Molecular genetic approaches for studying the etiology of diabetic nephropathy. Curr Mol Med. 2005;5(5):509-525.
39. Ng DP, Tai BC, Koh D, et al. Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia. 2005;48:1008-1016.
40. Fujisawa T, Ikegami H, Kawaguchi Y, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia. 1998;41:47-53.
41. Martins D, Tareen N, Norris KC. The epidemiology of end-stage renal disease among African Americans. Am J Med Sci. 2002;323:65-71.
42. Bowcock AM, Ruiz-Linares A, Tomfohrde J, et al. High resolution of human evolutionary trees with polymorphic microsatellites. Nature. 1994:368:455-457.
43. Risch N, Burchard E, Ziv E, et al. Migration blurs the definition of race conferred by continental boundaries. Genome Biol. 2002;3:7.
44. Schwartz RS. Racial profiling in medical research. N Engl J Med. 2001;344:1392-1393.
45. Tang H, Quertermous T, Rodriguez B, et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet. 2005;76:268-275.
46. Imperatore G, Hanson RL, Pettitt DJ, et al. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes. 1998;47:821-830.
47. Moczulski DK, Rogus JJ, Antonellis A, et al. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: results of novel discordant sib-pair analysis. Diabetes. 1998;47:1164-1169.
48. Bowden DW, Sale M, Howard TD, et al. Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy. Diabetes. 1997;46:882-886.
49. Iyengar S, Freedman BI, and the FIND Consortium. Genome-wide scans for diabetic nephropathy and proteinuria: The Family Investigation of Nephropathy and Diabetes (FIND). J Am Soc Neprhol. 2005;16:93A.
50. Sedor JR, Nelson RG, and the FIND Investigators. Diabetic nephropathy loci linked to glomerular filtration rate: The Family Investigation of Nephropathy and Diabetes (FIND). J Am Soc Nephrol. 2005;16:93A.